Boston Pharmaceuticals has appointed Ian Sanderson as chief financial officer. As a member of Boston Pharmaceuticals’ senior leadership team, Mr. Sanderson will be involved with the company’s evaluation, acquisition, and development of differentiated clinical programs for the Boston Pharmaceuticals drug portfolio.

Robert Armstrong, chief executive officer and co-founder of Boston Pharmaceuticals said, “Ian has extensive expertise in the evaluation and financing of clinical development programs, and brings to Boston Pharmaceuticals critical perspectives to our analyses of potential new product opportunities. We welcome him to our leadership team and look forward to his transaction and strategic insights as we build our portfolio of development programs through mutually advantageous collaborations with our partner companies.”

Mr. Sanderson joins Boston Pharmaceuticals from Catabasis Pharmaceuticals, where he was chief financial officer. While at Catabasis, Mr. Sanderson oversaw operations and led the company’s re-positioning and successful IPO in 2015. Prior to joining Catabasis, Mr. Sanderson was a senior advisor with JSB Partners, advising life sciences companies on corporate finance, M&A and business development transactions.